AnaptysBio (NASDAQ:ANAB) Trading Down 5.9%

AnaptysBio, Inc. (NASDAQ:ANAB)’s share price traded down 5.9% during mid-day trading on Thursday . The company traded as low as $20.10 and last traded at $20.20. 214,966 shares changed hands during trading, a decline of 31% from the average session volume of 311,290 shares. The stock had previously closed at $21.47.

Wall Street Analyst Weigh In

Several research firms have commented on ANAB. BTIG Research assumed coverage on shares of AnaptysBio in a report on Monday, February 26th. They issued a “buy” rating and a $55.00 target price on the stock. Leerink Partnrs restated an “outperform” rating on shares of AnaptysBio in a research report on Tuesday. Stifel Nicolaus started coverage on AnaptysBio in a report on Wednesday, February 21st. They issued a “buy” rating and a $50.00 target price on the stock. Piper Sandler initiated coverage on AnaptysBio in a research note on Friday, February 16th. They issued an “overweight” rating and a $80.00 price target on the stock. Finally, SVB Leerink initiated coverage on AnaptysBio in a research report on Tuesday. They set an “outperform” rating and a $47.00 price objective for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, AnaptysBio presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.22.

AnaptysBio Stock Up 0.2 %

The stock has a 50 day moving average price of $23.25 and a 200 day moving average price of $20.56.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. The business had revenue of $9.01 million during the quarter, compared to analysts’ expectations of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. On average, sell-side analysts predict that AnaptysBio, Inc. will post -6.17 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Eric J. Loumeau sold 5,000 shares of AnaptysBio stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the sale, the insider now directly owns 3,240 shares in the company, valued at approximately $81,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Daniel Faga sold 145,940 shares of the business’s stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total value of $3,324,513.20. Following the sale, the chief executive officer now owns 752,087 shares of the company’s stock, valued at $17,132,541.86. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Eric J. Loumeau sold 5,000 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the sale, the insider now owns 3,240 shares of the company’s stock, valued at $81,000. The disclosure for this sale can be found here. Insiders sold 157,005 shares of company stock valued at $3,586,199 over the last quarter. 35.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in shares of AnaptysBio by 2.1% during the first quarter. BlackRock Inc. now owns 1,895,494 shares of the biotechnology company’s stock worth $41,246,000 after acquiring an additional 39,228 shares during the last quarter. Vanguard Group Inc. raised its holdings in AnaptysBio by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,745,108 shares of the biotechnology company’s stock worth $44,518,000 after purchasing an additional 14,638 shares during the last quarter. State Street Corp lifted its position in shares of AnaptysBio by 10.0% in the 3rd quarter. State Street Corp now owns 1,271,727 shares of the biotechnology company’s stock worth $32,442,000 after purchasing an additional 115,846 shares during the period. First Light Asset Management LLC boosted its stake in shares of AnaptysBio by 56.4% in the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock valued at $26,500,000 after purchasing an additional 446,372 shares during the last quarter. Finally, Woodline Partners LP increased its position in shares of AnaptysBio by 125.1% during the second quarter. Woodline Partners LP now owns 1,034,549 shares of the biotechnology company’s stock worth $21,043,000 after buying an additional 574,987 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.